Ionis Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ionis Pharmaceuticals (IONS).

Price Target Range — 6 Quarters

Analyst Consensus — 21 Analysts

1S.Buy

16Buy

4Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$86Upside to Avg. PT+96.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$100
Sep 22, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$76→$70
Sep 15, 2026	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$89→$80
Sep 9, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$90→$85
Sep 8, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$110→$104
Sep 8, 2026	Goldman Sachs	Salveen Richter	PT Cut	Neutral	$69→$56
Sep 8, 2026	BMO Capital	David Lebowitz	PT Cut	Market Perform	$61→$54
Sep 8, 2026	Canaccord Genuity	Gary Nachman	PT Cut	Buy	$95→$85
Sep 8, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$115→$100
Sep 4, 2026	Needham	Joseph Stringer	Maintained	Buy	$86
Sep 4, 2026	BMO Capital	David Lebowitz	PT Raise	Market Perform	$60→$61
Sep 4, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$115
Aug 31, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$115
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform→Market Perform	$60
Aug 3, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$72→$76
Jul 30, 2026	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$100→$95
Jul 30, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$125→$115
Jul 21, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$106→$89
Jul 16, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Jul 13, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$100→$85

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $110 to $104.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.

Benzinga Newsdesk

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

PRO
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

PRO
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

PRO
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

PRO
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104

PRO
Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56

People Also Watch

People Also Watch

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

PROJP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

PROGuggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

PROBarclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

PROMorgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104

PROGoldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

PRO
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

PRO
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

PRO
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

PRO
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104

PRO
Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56